SCHEMBL6928147

SCHEMBL6928147

Cc1nc(OCc2ccncc2)ccc1C(=O)N[C@H](C)C1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 1/20 0.48
WDR5 P61964 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
JAK3 P52333 1/20 0.41
P2RX7 Q99572 2/20 0.41
CNR2 P34972 5/20 0.41
CNR1 P21554 4/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMYD3 Q9H7B4 1/20 0.39
GABRA5 P31644 1/20 0.39
ABHD12 Q8N2K0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2159803 0.84 GRM5 (0.49) WDR5CNR2CNR1KDM4EALDH1A1
SCHEMBL1462248 0.84 GRM5 (0.49) WDR5CNR2CNR1KDM4EALDH1A1
SCHEMBL2158698 0.84 GABRA5 (0.51) KDM4EALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL2158694 0.84 GABRA5 (0.51) KDM4EALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL6930043 0.83 SMYD3 (0.45) JAK2JAK1JAK3CNR2CNR1
SCHEMBL6928005 0.78 GABRA5 (0.51) GABRA5
SCHEMBL6927899 0.77 CNR1 (0.47) WDR5CNR2CNR1KDM4EALDH1A1
SCHEMBL6930244 0.74 CNR1 (0.46) WDR5CNR2CNR1KDM4EALDH1A1
SCHEMBL6930316 0.74 CNR1 (0.48) WDR5CNR2CNR1KDM4EALDH1A1
SCHEMBL1462220 0.74 NOX1 (0.54) NOX1KDM4EALDH1A1GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
WO-2011035324-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS VANDERBILT UNIVERSITY (US) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS GRM5, GRIK5, GRM1 NOX1 824/4885WDR5 449/4885JAK2 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.